Clover Health Investments Corp.

Clover Health Investments Corp. has seen notable stock performance, with significant gains over various timeframes, contrasting sharply with the S&P 500's declines. The company reports strong fundamentals, including a high compound annual growth rate in net sales, despite recent profit challenges and a solid level of institutional ownership.

Clover Health Investments Corp. has achieved a new 52-week high of USD 5.14, significantly up from its low of USD 1.58. With a market cap of approximately USD 971 million, the company operates in the insurance sector and has shown relative strength, outperforming the S&P 500 over the past year.

Clover Health Investments Corp. has seen a notable rise in stock performance, with significant gains over the past week and month. The company reported strong fundamentals, including a high compound annual growth rate in net sales and record operating cash flow, while maintaining substantial institutional interest.

Clover Health Investments Corp. has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, operating in the insurance sector with a market cap of around USD 971 million, has outperformed the S&P 500, despite facing ongoing financial losses.

Clover Health Investments Corp. has seen a notable rise in its stock price, achieving significant monthly and year-to-date gains. The company reported strong financial results, including a substantial increase in net sales and operating cash flow. However, it continues to face long-term performance challenges and underperformed the market over the past year.

Clover Health Investments Corp. has achieved a new 52-week high of USD 4.22, significantly up from its low of USD 1.58. The company, with a market cap of USD 1,093 million, has outperformed the S&P 500 over the past year, despite operating at a loss and having a high debt-equity ratio.

Clover Health Investments Corp. has reached a new 52-week low, reflecting ongoing struggles in a challenging market. Over the past year, the company's stock has significantly declined, with negative financial metrics including a return on equity of -16.93% and a pre-tax profit loss of -10.58 million USD.

Clover Health Investments Corp. has recently experienced a revision in its evaluation amid active market participation. The stock has shown notable fluctuations and mixed technical indicators. While it has outperformed the S&P 500 in the short term, longer-term returns present a more complex scenario, indicating both opportunities and challenges.

Clover Health Investments Corp. has seen notable stock activity, with a significant intraday high. The company has outperformed the S&P 500 over various time frames, though its long-term fundamentals reveal challenges, including negative return on equity and ongoing losses, indicating a complex financial situation.

Clover Health Investments Corp. experienced a significant one-day stock performance, outperforming the S&P 500. Despite recent gains and a strong monthly rise, the company faces long-term challenges, including stagnant operating profit growth and a low average Return on Equity. Its market capitalization is around USD 1,456 million.

Clover Health Investments Corp. has experienced a challenging year, with a significant decline in stock performance compared to the S&P 500. Recent evaluations show mixed technical indicators, reflecting ongoing struggles in the insurance sector. The company's long-term performance also reveals a substantial drop over the past five years.

Clover Health Investments Corp. has recently revised its evaluation amid changing market dynamics. The stock has shown fluctuations, with a notable return of 11.50% over the past year. Recent trends indicate a potential recovery phase, despite a challenging five-year performance and mixed technical indicators.

Clover Health Investments Corp., a small-cap insurance company, experienced a notable stock movement on September 23, 2025. Year-to-date, it has outperformed the S&P 500, with significant profit growth. However, challenges remain, including a negative return on equity and no dividend yield, highlighting concerns about its long-term fundamentals.